Androgen-mediated resistance to apoptosis

Prostate

Volumn 53, Issue 4, 2002, Pages 300-309

  Coffey, Ronan N T ^a   Watson, R William G ^a   O'Neill, Amanda J ^a   Mc Eleny, Kevin ^a   Fitzpatrick, John M ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Androgen; Apoptosis; Bcl 2; Caspases; NF B

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; CASPASE; ETOPOSIDE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN ISOLATION; RADIATION DOSE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION;

APOPTOSIS; CASPASES; DIHYDROTESTOSTERONE; HUMANS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0036892260     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10159     Document Type: Article

References (39)

1. Hakimi JM, Rondinelli RH, Schoenberg MP, Barrack ER. Androgen-receptor gene structure and function in prostate cancer. World J Urol 1996;14:239-337.
2. Berges R, Isaacs JT. Programming events in the regulation of cell proliferation and death. Clin Cancer Res 1993;1:473-480.
3. Saeed B, Zhang H, Shi-Chung N. Apoptotic program is initiated but not completed in LNCaP cells in response to growth in charcoal-stripped media. Prostate 1997;31:145-152.
4. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000;7:997-1007.
5. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand E, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
6. Lee C, Sutkowski DM, Sensibar J, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995;136:796-803.
7. Kim IY, Zelner DJ, Sensibar JA, Ahn HJ, Park L, Kim JH, Lee C. Modulation of sensitivity to transforming growth factor-beta 1 (TGF-beta 1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone. Exp Cell Res 1996;222:103-110.
8. Jakowlew SB, Moody TW, Mariano JM. Transforming growth factor-beta receptors in human cancer cell lines: Analysis of transcript, protein and proliferation. Anticancer Res 1997;17: 1849-1860.
9. Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Singerland J. Involvement of the p27kip1 in G1 arrest by high dose 5a-dihydrotestosterone in the LNCaP human prostate cancer cells. Oncogene 2000;19:670-679.
10. Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM. Androgen induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 2000;141:1699-1704.
11. Keller ET, Chang C, Ershler WB. Inhibition of NF-KappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 1996;271:26267-26275.
12. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphotidyylinostol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999;59:2891-2897.
13. Kassen AE, Sensibar JA, Sintich SM, Pruden SJ, Kozlowski M, Lee C. Autocrine effect of DHT on FGF signaling and cell proliferation in LNCaP cells: Role of heparin/heparin-degrading enzymes. Prostate 2000;44:124-132.
14. Okamato M, Lee C, Oyasu R. Autocrine effect of androgen on proliferation of an androgen responsive prostatic carcinoma cell line, LNCaP: Role of interleukin-6. Endocrinology 1997;138: 5071-5074.
15. Limonta P, Dondi D, Marcelli MM, Moretti RM, Negri-Cesi P, Motta M. Growth of the androgen-dependent tumor of the prostate: Role of androgens and of locally expressed growth modulatory factors. J Steroid Biochem Mol Biol 1995;53:401-405.
16. Kabler RL, Srinivasan A, Taylor LJ, Mowad J, Rothblum LI, Cavanaugh AJ. Steroid Biochem Mol Biol 1996;59:431-439.
17. Myers RB, Oelschlager DK, Hockett RD, Conway-Myers BA, Grizzle WE. The effects of dihydrotestosterone on the expression of p185(erb-2) and c-erb-2 mRNA in the prostatic cell line LNCaP. J Steroid Biochem Mol Biol 1996;59:441-447.
18. Lim JD, Hasagawa M, Sikes C, Khoo VS, Terry NHA, Zagars GK, Meistrich M, Pollack A. Supra-additive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997;38:1071-1077.
19. Pollack A, Ashoori F, Sikes C, Joon DL, von Ecshenbach AC, Zagars GK, Meistrich ML. The early supra-additive response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int J Radiat Oncol Biol Phys 1999;46:153-158.
20. Berchem GY, Bosseler M, LaVencia Y, Voeller HJ, Zeitlin S, Gelmann EP. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995;55: 735-738.
21. Kyprianou N, King ED, Bradbury D, Rhee JG. Bcl-2 over-expression delays radiation induced apoptosis without effecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997;70:341-348.
22. Kajiwara T, Takeuchi T, Ueki T, Moriyama N, Ueki K, Kakizoe T, Kawabe K. Effect of Bcl-2 expression in human prostate cancer cells in vitro and in vivo. Int J Urol 1999;10:520-525.
23. Marti A, Jaggi R, Vallan C, Ritter PM, Baltzer A, Srinivasan A, Dharmarajan AM, Friis R. Physiological apoptosis in hormone-dependent tissues: Involvement of the caspases. Cell Death Differ 1999;6:1190-2000.
24. Coffey RNT, Watson RWG, Fitzpatrick JM. Signaling for the caspases: Their role in prostate cell apoptosis. J Urol 2001;165:5-14.
25. Winters RN, Kramer K, Borkowski A, Kyprianou N. Loss of caspase-1 and caspase-3 expression in human prostate cancer. Cancer Res 2001;61:1227-1232.
26. O'Neill AJ, Coffey RNT, Hegarty NJ, O'Keane CK, Fitzpatrick JM, Watson RWG. Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma. Prostate 2001; 47:1-6.
27. Muenchen HJ, Lin D, Walsh MA, Keller ET, Pienta KJ. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB an I-kappaB-alpha "super-repressor." Clin Cancer Res 2000;6: 1969-1977.
28. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 1999;35:167-174.
29. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999;18:7389-7394.
30. Suimitomo M, Tachibana M, Nakashima J, Murai M, Miyajima A, Kimura F, Hayakawa M, Nakamura H. An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. J Urol 1999;161:674-679.
31. Coffey RNT, Watson RWG, Hegarty NJ, O'Neill AJ, Gibbons N, Brady HR, Fitzpatrick JM. Thiol mediated apoptosis in prostate carcinoma cells. Cancer 2000;88:2092-2104.
32. Balla A, Toth B, Timar G, Bak J, Krajcsi P. Molecular targets for pharmacological cytoprotection. Biochem Pharmacol 2001;61: 769-777.
33. Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 2000;32:1123-1136.
34. Peng L, Deepak N, Budihardj I, Srinivasula S, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:489-495.
35. Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: The proteases of the apoptotic pathway. Oncogene 1998;7:237-245.
36. Bruckheimer EM, Kyprianou N. Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone- sensitive prostate cancer cells. Endocrinology 2001;142:2419- 2426.
37. Bruckheimer EM, Gjertsen BT, McDonnell TJ. Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. Semin Oncol 1999;4:382-398.
38. Chaudhary KS, Abel PD, Lalani EN. Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect 1999;7:49-57.
39. Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R. Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst 1999;91:1227-1232.